A strategy of vascular‐targeted therapy for liver fibrosis
Yuan Lin, Meng‐Qi Dong, Zhi‐Min Liu, Meng Xu, Zhi‐Hao Huang, Hong‐Juan Liu, Yi Gao, Wei‐Jie Zhou – 22 December 2021
Yuan Lin, Meng‐Qi Dong, Zhi‐Min Liu, Meng Xu, Zhi‐Hao Huang, Hong‐Juan Liu, Yi Gao, Wei‐Jie Zhou – 22 December 2021
Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Ross Laybutt, Sof Andrikopoulous, Ian E. Alexander, Mathew J. Watt, Peter W. Angus, Chandana B. Herath – 22 December 2021 – Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is frequently associated with type 2 diabetes. However, there is no specific medical therapy to treat this condition. Angiotensin‐converting enzyme 2 (ACE2) of the protective renin angiotensin system generates the antifibrotic peptide angiotensin‐(1‐7) from profibrotic angiotensin II peptide.
Tran Nguyen, Trang Pham, Loc Phan, Gary Mize, Amy Trang, Diem Dao, Anh Le, Robert Gish, William M. Lee, Dung Do, Hong K. Tang, Hai T. Phan, Binh T. Nguyen, Doan Y Dao – 22 December 2021
Camille A. Kezer, Vijay H. Shah, Douglas A. Simonetto – 22 December 2021
Francesca Cingolani, Yunshan Liu, Yang Shen, Jing Wen, Alton B. Farris, Mark J. Czaja – 21 December 2021 – Activation of extracellular signal–regulated kinase (ERK) 1/2 promotes hepatocyte proliferation in response to growth stimuli, but whether constitutive hepatocyte ERK1/2 signaling functions in liver physiology is unknown. To examine the role of ERK1/2 in hepatic homeostasis, the effects of a knockout of Erk1 and/or Erk2 in mouse liver were examined. The livers of mice with a global Erk1 knockout or a tamoxifen‐inducible, hepatocyte‐specific Erk2 knockout were normal.
Xinrong Zhang, Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Lilian Yan Liang, Vicki Wing‐Ki Hui, Huapeng Lin, Guan‐Lin Li, Jimmy Che‐To Lai, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong – 21 December 2021
Anthony Tanoto Tan, Fanping Meng, Jiehua Jin, Ji‐Yuan Zhang, Si‐Yu Wang, Lei Shi, Ming Shi, Yuanyuan Li, Yunbo Xie, Li‐Min Liu, Chun‐Bao Zhou, Alicia Chua, Zi Zong Ho, Junqing Luan, Jinfang Zhao, Jing Li, Lu‐En Wai, Sarene Koh, Tingting Wang, Antonio Bertoletti, Fu‐sheng Wang – 20 December 2021 – The application of hepatitis B virus (HBV)–T‐cell receptor (TCR) T‐cell immunotherapy in patients with HBV‐related hepatocellular carcinoma (HBV‐HCC) has been apathetic, as the expression of HBV antigens by both normal HBV‐infected hepatocytes and HCC cells with HBV‐DNA integration increases the ri
David D. Lee – 20 December 2021
Alexander Laemmle, Johannes Häberle, Holger Willenbring – 20 December 2021
Tania Colasanti, Alessandra Di Giamberardino, Alessio Grimaldi, Vincenzo Cardinale, Guido Carpino, Carmine Mancone – 19 December 2021